Dxcover

Dxcover is a medical diagnostics company that has developed a multi-omic liquid biopsy platform for early cancer detection, powered by light spectroscopy and machine learning algorithms. The company's platform, known as the Dxcover Platform, combines novel hardware with AI to analyze blood samples and detect multiple cancer types through multi-omic spectral analysis, with first applications in earlier diagnosis of brain tumors, pancreatic cancer, and ovarian cancer. The platform's DROP DRY DETECT technology uses infrared spectroscopy to capture a molecular fingerprint of the blood sample, which is then analyzed by machine learning algorithms to identify cancer-specific biomarker patterns, enabling detection at earlier stages than conventional methods. Dxcover's mission is to deploy the platform for triage of high-risk populations for high-mortality cancers to enable individuals to access value-based cancer care, with a vision to be a world leader in liquid biopsy and artificial intelligence for early detection of cancers and other diseases. The platform is designed for biopharma and diagnostic partnering applications beyond its current cancer indications, with potential applications in other diagnostic and therapeutic areas. The company addresses the urgent global unmet need for early cancer detection, where cancer is the leading cause of death under age 85 in the USA and someone is diagnosed with cancer every few seconds. Founded in 2016 and headquartered in Glasgow, United Kingdom, with US operations in Franklin, Tennessee, Dxcover has raised $21.4M in Series A funding from investors including EIC Fund, Europa, Norcliffe Capital, SIS Ventures, University of Strathclyde, Scottish Enterprise, Mercia, Eos Advisory, Investment Fund for Scotland, and Macmillan Cancer Support.